Pasar al contenido principal

Anna Rosell Novel

Licenciada en Biología (2001) y Doctora en Medicina (2005), por la Universidad Autónoma de Barcelona. Mi formación científica y experiencia se han centrado en el estudio traslacional de la enfermedad y las terapias del ictus. Obtuve una plaza de investigadora Miguel Servet en 2010 en el Instituto Nacional de Sanidad y Agencia de Investigación (Instituto Carlos III), y desde febrero de 2016 soy investigadora estabilizada del VHIR como Investigadora Principal y Jefe del Laboratorio de investigación en Enfermedades Neurovasculares.

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurovasculares
Vall Hebron Institut de Recerca
Anna Rosell Novel

Anna Rosell Novel

Anna Rosell Novel

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurovasculares
Vall Hebron Institut de Recerca

Licenciada en Biología (2001) y Doctora en Medicina (2005), por la Universidad Autónoma de Barcelona. Mi formación científica y experiencia se han centrado en el estudio traslacional de la enfermedad y las terapias del ictus. Obtuve una plaza de investigadora Miguel Servet en 2010 en el Instituto Nacional de Sanidad y Agencia de Investigación (Instituto Carlos III), y desde febrero de 2016 soy investigadora estabilizada del VHIR como Investigadora Principal y Jefe del Laboratorio de investigación en Enfermedades Neurovasculares.

-

Líneas de investigación

L4 Neurorepair

New therapies beyond the hyperacute phase of stroke are needed to be able to treat much more patients in delayed phases of this devastating disease. The idea that neurovascular plasticity contributes to stroke recovery can be a powerful concept for stroke therapy. Obviously, the therapeutic time window for interventions based on promoting recovery would be much larger than those for targeting acute stroke.  In this context, long-term neuroreparative therapies will  have to target the two essential phenomena to achieve brain neurorecovery after stroke: to restore the cerebral blood flow and to promote Neuroregeneration.


To achieve these major goals, both angiogenesis and neurogenesis need to be enhanced in the ischemic brain.


Classically, the formation of new blood vessels was thought to be mediated exclusively by embryogenic vasculogenesis followed by the sprouting of endothelial cells from preexisting vessels during angiogenesis. In the last decade, this standard dogma was overturned with the identification of the existence of circulating bone marrow-derived endothelial progenitor cells (EPCs). These cells are capable of differentiating, ex vivo, into endothelial-phenotyped cells, and now comprise a new model for endothelial generation and vessel repair (Asahara et al., 1997). These cells comprise a potential cell-based and growth-factor source of an alternate approach to enhance angio-neurogenic responses. In fact, newborn neurons (neurogenesis) and new vascular components (angiogenesis) form a microenvironment that has been termed the neurovascular niche [Ohab et al., 2006] were angiogenesis and neurogenesis are linked thorough specific growth factors.


Angiogenesis and neurogenesis occur endogenously after stroke. Our goal is to study these two complex phenomena both in experimental and human studies to finally potentiate them correctly to improve brain function and neurorecovery after stroke.


Experimental Models and Techniques


In vivo stroke models:

Cerebral ischemia affecting the cortical territory of the Middle Cerebral Artery (MCA) is occluded at the level of the M1 portion (distal occlusion). This model has been chosen because presents very low mortality rates allowing long-term studies. Besides, the infarct is restricted to the cortex with clear boundary areas with normal cerebral blood flow and never affects neuroblast-rich areas such as the subventricular zone (then, both angiogenesis and neurogenesis can occur).


Functional outcome is assessed by the cylinder and corner tests which have been reported to be appropriate test for this type of cortical infarcts. Besides, histology and immunohistochemistry studies are conducted to evaluate brain repair and angio-neurogenic processes.

                 

Endothelial Progenitor Cell Cultures:

EPCs are obtained from the Mononuclear cell fraction of human blood and from mouse spleen. MNCs are cultured in fibronectin-coated plates with complete cell culture medium EGM-2MV.

   

Both in human and murine cell cultures yield an early EPC population (also called Circulating Angiogenic Cells) obtained at day 4-7 after plating and late outgrowth EPC colonies (also called Endothelial Colony Forming Cells) appear from day 10 as colonies with high proliferation capacity and tubulogenic capacity.


In vitro Oxygen-Glucose Deprivation: endothelial cells and Endothelial progenitor cells are challenged to a transitory Oxygen and Glucose deprivation to study their angio-vasculogenic responses to ischemia and to test how potential treatments that could modify these responses.


Angiogenesis-related techniques: angio-vasculogenic mechanisms are studied in a variety of in vitro assays including Matrigel® tubulogenesis, cell migration using trans-well assays or cell adhesion to a mature monolayer of endothelial cells. Our studies focus on the angio-vasculogenic responses of both Endothelial Progenitor Cells and mature endothelial cells such as the human cell line of microvascular endothelial cells (hCMEC/D3).

   

NMR Imaging: Bruker-BIOSPEC 70/30 USR, 7 T Preclinical MRI System is used for the neuroimaging studies. Neuroimaging studies are conducted in vivo to follow-up the ischemic lesion. Specific sequences are performed to assess axonal degeneration/regeneration and changes in cerebral blood flow and angiogenesis.


IP: Anna Rosell Novel

Proyectos

Administració endovascular de nanomaterials terapèutics per la recuperació de l’ictus.

IP: Anna Rosell Novel
Colaboradores: Anna Penalba Morenilla, Kerrie Adrián Campbell, Miguel García Gabilondo
Entidad financiadora: Fundació La Marató de TV3
Financiación: 173750
Referencia: MARATO/205/C/2023
Duración: 22/04/2024 - 21/04/2027

Beca VHIR PhD

IP: Anna Rosell Novel
Colaboradores: Sira Rodrigo Bosch, Laia Perez Lasarte, Marta Kinga Klimczak , Marta Kinga Klimczak
Entidad financiadora: Fundació Institut de Recerca HUVH
Financiación: 69188.74
Referencia: VPHD/MARTA_K
Duración: 15/05/2023 - 14/05/2026

Malalties neurovasculars

IP: Anna Rosell Novel
Colaboradores: Mercedes Arrue Gonzalo, Joan Montaner Villalonga, Marcel Lamana Vallverdu, Anna Penalba Morenilla, Malalties neurovasculars, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Antonio Palasi Franco, Jesús Pizarro Gonzálvez, Paula Garcia Rodriguez, Miguel García Gabilondo, Nicolas Garcia Rodriguez
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 40000
Referencia: 2021 SGR 00656
Duración: 01/01/2022 - 30/06/2025

Tratamientos endovasculares de neuroprotección y neuroreparación en la recuperación del ictus.

IP: Anna Rosell Novel
Colaboradores: Anna Penalba Morenilla, Paula Garcia Rodriguez, Miguel García Gabilondo
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 141570
Referencia: PI22/01055
Duración: 01/01/2023 - 31/12/2025

Noticias relacionadas

El programa de formación doctoral de excelencia liderado por la Universidad Autónoma de Barcelona TOUCH MSCA-COFUND, centrado en el ámbito de la salud mental, ha abierto su primera convocatoria, dotada con 13 plazas.

Los grupos de Enfermedades Cardiovasculares y Enfermedades Neurovasculares del VHIR investigarán nuevas estrategias terapéuticas para la insuficiencia cardíaca, nanomedicina en ictus y prevención de la toxicidad cardiovascular en tratamientos de cáncer.

La Comisión de Salud y Medio Ambiente ha impulsado la instalación de plafones situados en los diferentes vestíbulos del hospital en los que se puede ver una silueta humana acompañada de los 17 tipos de enfermedades que causa la contaminación.

Profesionales relacionados

Laura Hidalgo Corbacho

Laura Hidalgo Corbacho

Investigador predoctoral
Diabetes y Metabolismo
Leer más
Marcos Malumbres

Marcos Malumbres

Investigador/a principal
Leer más
Humaira Abdul Ghafoor

Humaira Abdul Ghafoor

Investigador predoctoral
Leer más
Bastien Debieve

Bastien Debieve

Tècnic/a Grau Superior
Unidad Internacional
Dirección de Investigación Competitiva
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.